NEDD4 E3 ubiquitin protein ligaseGenealiases: NEDD4-1 · RPF1
Q-omics provides the consensus-scored NEDD4 profile across patient tissues and cancer cell-line models. NEDD4 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, NEDD4 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, NEDD4 protein abundance shows 31,356 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, HNSC, and GBM as cancer lineages where NEDD4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NEDD4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NEDD4 survival associations across molecular data types. NEDD4 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (8) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NEDD4 RNA expression–survival associations across cancer types. High NEDD4 expression shows unfavorable associations in MESO, KICH, LUAD, SCLC and LGG, but favorable associations in KIRC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for NEDD4 RNA expression.
This table summarizes NEDD4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NEDD4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NEDD4 shows lower tumor expression in UCEC and KICH and higher tumor expression in HNSC, KIRC, LIHC and COAD. The HNSC box plot shows higher NEDD4 RNA expression in tumor versus normal tissue (log2 FC = +1.728, t-test p < 0.001).
This table shows molecular features associated with NEDD4 in patient tissues and cancer cell lines. In patient samples, NEDD4 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NEDD4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
